Mckesson Corp

MCK

829.149USD

+6.849+0.83%

Market hours （ET）Quotes delayed by 15 min

Mckesson Corp's Score

Industry at a Glance

Industry Ranking

4 / 159

Overall Ranking

23 / 4540

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Mckesson Corp Highlights

StrengthsRisks

McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 359.05B.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 29.76% year-on-year.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 10.68%.

Fairly Valued

The company’s latest PE is 25.59, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 111.50M shares, decreasing 3.77% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 5.37K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.19.

Analyst Rating

Based on 18 analysts

Buy

Current Rating

942.406

Target Price

+12.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Mckesson Corp is 8.92, ranking 27 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 103.15B, representing a year-over-year increase of 10.14%, while its net profit experienced a year-over-year increase of 360.58%.

Score

Industry at a Glance

Previous score

8.92

Change

0



Financials

5.29

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.48

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.85

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Mckesson Corp is 8.51, ranking 17 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 25.59, which is 33.73% below the recent high of 34.22 and 45.17% above the recent low of 14.03.

Score

Industry at a Glance

Previous score

8.51

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 4/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Mckesson Corp is 8.44, ranking 35 out of 159 in the Pharmaceuticals industry. The average price target is 955.00, with a high of 1000.00 and a low of 757.50.

Score

Industry at a Glance

Previous score

8.44

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Mckesson Corp is 7.46, ranking 48 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 849.37 and the support level at 794.91, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.90

Change

-1.44

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-01-29

The current institutional shareholding score of Mckesson Corp is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 90.34%, representing a quarter-over-quarter decrease of 0.29%. The largest institutional shareholder is The Vanguard, holding a total of 11.97M shares, representing 9.70% of shares outstanding, with 2.98% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

11.97M

-0.35%

BlackRock Institutional Trust Company, N.A.

6.79M

+0.76%

State Street Investment Management (US)

5.75M

+0.90%

MFS Investment Management

3.85M

-1.78%

Geode Capital Management, L.L.C.

2.83M

+0.41%

Fidelity Management & Research Company LLC

2.74M

+43.63%

AllianceBernstein L.P.

2.39M

+5.59%

Putnam Investment Management, L.L.C.

2.35M

+3.62%

Norges Bank Investment Management (NBIM)

1.84M

-12.75%

JP Morgan Asset Management

1.68M

-51.21%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Mckesson Corp is 9.62, ranking 8 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.41. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Mckesson Corp

MCK

8.65 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.89 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.79 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

8.77 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

ANI Pharmaceuticals Inc

ANIP

8.65 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

8.62 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment